Alzheimer
Alzheimer
Evidence suggests that the latest discovery is that many neurodegenerative disorders have a common biochemical feature which is the abnormal protein deposits. This biochemical feature causes the occurrence of neuronal dysfunction. Alzheimer’s disease has in recent years risen at a high speed something that has made healthcare industry develop strategies on how to get suitable treatment methods. Different treatment strategies have been developed due to the complexity of the Alzheimer’s disease (AD).
Clinical and scientific research have developed a number of treatment strategies that physicians current use in treatment of Alzheimer’s disease. Some of the common, current treatment strategies used includes normalization of Ach, normalization of Glu, inhibition of amyloid formation, inhibition of tau hyperphosphorylation, hormone therapy, miscellaneous therapeutic agents and targeting β-Amyloid Metabolism, (Grossberg et al., 2007).
Normalizing neurotransmitter systems have been discovered to be among the current treatment strategies of AD. A number of abnormalities affect patients suffering from the above disease thus several treatment strategies under normalizing neurotransmitter systems helps physicians provide relevant treatment services. Some of the strategies include cholinergic system and glutamatergic system among others. Under such system, there are different approaches used depending on the nature of AD. Physicians who apply cholinergic system strategy in their treatment may use rivastigmine, donepezil, or galantamine in treating patients.
With glutamatergic system strategy, there are two common approaches used and they include neramexane and memantine treatment strategies, (Birks & Harvey, 2011).Targeting β-Amyloid Metabolism is another strategy that physicians use in treating Alzheimer’s disease. The strategy helps in establishing the presence of amyloid in the human body. Secretase inhibitors, anti-aggregation agents, vaccines, and metal chelators are some of the common approaches used in AD treatment under targeting β-Amyloid Metabolism strategy, (Grossberg et al., 2007).
Reference:
Is this your assignment or some part of it?
We can do it for you! Click to Order!
